{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "27",
                "@timestamp": "2023-05-27T06:25:41.000041-04:00",
                "@year": "2023",
                "@month": "05"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2023",
                "@month": "04"
            }
        },
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University and King Chulalongkorn Memorial Hospital"},
                                {"$": "Thai Red Cross Society"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "103183427"
                                },
                                {"@afid": "60031780"},
                                {"@afid": "60022183"},
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948250921-eb44978d7a0c88d631a85ba1f417a6d5-1",
                            "ce:source-text": "Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand",
                            "@dptid": "103183427"
                        },
                        "author": [
                            {
                                "ce:given-name": "Thanin",
                                "preferred-name": {
                                    "ce:given-name": "Thanin",
                                    "ce:initials": "T.",
                                    "ce:surname": "Asawavichienjinda",
                                    "ce:indexed-name": "Asawavichienjinda T."
                                },
                                "@author-instance-id": "OB2BibRecID-948250921-54c2957bb043761698f5004fb95ca7d6-1",
                                "@seq": "1",
                                "ce:initials": "T.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Asawavichienjinda",
                                "@auid": "6603247860",
                                "@orcid": "0000-0002-3119-2610",
                                "ce:indexed-name": "Asawavichienjinda T."
                            },
                            {
                                "ce:given-name": "Seelwan",
                                "preferred-name": {
                                    "ce:given-name": "Seelwan",
                                    "ce:initials": "S.",
                                    "ce:surname": "Sathitratanacheewin",
                                    "ce:indexed-name": "Sathitratanacheewin S."
                                },
                                "@author-instance-id": "OB2BibRecID-948250921-49799c3b92752e109435f8e5198a6830-1",
                                "@seq": "2",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Sathitratanacheewin",
                                "@auid": "57199324342",
                                "@orcid": "0000-0002-6286-6534",
                                "ce:indexed-name": "Sathitratanacheewin S."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Division of Cardiology"},
                                {"$": "Department of Medicine"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University and King Chulalongkorn Memorial Hospital"},
                                {"$": "Thai Red Cross Society"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "103183427"
                                },
                                {"@afid": "60031780"},
                                {"@afid": "60022183"},
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948250921-3edd28f0297e061af9c48e704da89d59-1",
                            "ce:source-text": "Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand",
                            "@dptid": "103183427"
                        },
                        "author": [{
                            "ce:given-name": "Ronpichai",
                            "preferred-name": {
                                "ce:given-name": "Ronpichai",
                                "ce:initials": "R.",
                                "ce:surname": "Chokesuwattanaskul",
                                "ce:indexed-name": "Chokesuwattanaskul R."
                            },
                            "@author-instance-id": "OB2BibRecID-948250921-42e3e532e84e18bc50f2537b49dc1bb5-1",
                            "@seq": "3",
                            "ce:initials": "R.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Chokesuwattanaskul",
                            "@auid": "57202543782",
                            "ce:indexed-name": "Chokesuwattanaskul R."
                        }]
                    }
                ],
                "citation-title": "\u201cWearing-off\u201d efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials",
                "abstracts": "Â© The Author(s) 2023.Background: A new migraine prevention, CGRP monoclonal antibodies (mAbs), is injectable on a monthly or quarterly basis. In clinical practice, some patients reported that drug effectiveness does not last until the upcoming scheduled injection, a so-called \u201cwearing-off\u201d effect. We aimed to evaluate the wearing-off effect of the CGRP mAbs for migraine prevention in patients with different monthly migraine days. Methods: We conducted a literature search for studies that reported migraine frequency after CGRP monoclonal antibody administration from MEDLINE, SCOPUS, Web of Science, and Cochrane Database from inception through February 2022. A meta-analysis, random-effects model was applied to assess the difference in migraine frequency between early and later weeks after medication to assess the presence of a wearing-off effect. Risk ratio was calculated to report the pooled treatment effect. Results: Four studies were entered for the analysis, comprising 2409 patients in randomized controlled trials. There was no association between CGRP mAbs and wearing-off effect in patients with galcanezumab with a pooled risk ratio of 1.29 (95% CI 0.73 to 2.28) compared to placebo group. However, there was an association between galcanezumab and wearing-off effect in patients with chronic migraine with a pooled risk ratio of 1.91 (95% CI 1.11 to 3.28) compared to placebo group. Conclusion: In this meta-analysis, there was a wearing-off efficacy of galcanezumab but only in a small percentage of patients with chronic migraine in randomized controlled trials.",
                "correspondence": {
                    "affiliation": {
                        "country": "Thailand",
                        "@country": "tha",
                        "city": "Bangkok",
                        "organization": [
                            {"$": "Division of Cardiology"},
                            {"$": "Department of Medicine"},
                            {"$": "Faculty of Medicine"},
                            {"$": "Chulalongkorn University and King Chulalongkorn Memorial Hospital"},
                            {"$": "Thai Red Cross Society"}
                        ],
                        "@affiliation-instance-id": "OB2BibRecID-948250921-4f49d0654254990b48adcc16c0e54f1b-1",
                        "ce:source-text": "Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand"
                    },
                    "person": {
                        "ce:given-name": "Ronpichai",
                        "@author-instance-id": "OB2BibRecID-948250921-d155088b1f72ae479f790592153be19e-1",
                        "ce:initials": "R.",
                        "ce:surname": "Chokesuwattanaskul",
                        "ce:indexed-name": "Chokesuwattanaskul R."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "CGRP monoclonal antibodies",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "effect",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "migraine prevention",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "prophylaxis",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Wearing-off efficacy",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "https://journals.sagepub.com/home/CEP",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Cephalalgia",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {"voliss": {
                        "@volume": "43",
                        "@issue": "4"
                    }},
                    "@type": "j",
                    "sourcetitle": "Cephalalgia",
                    "publicationdate": {
                        "month": "04",
                        "year": "2023",
                        "date-text": "April 2023",
                        "day": "01"
                    },
                    "codencode": "CEPHD",
                    "sourcetitle-abbrev": "Cephalalgia",
                    "@country": "gbr",
                    "issn": [
                        {
                            "$": "14682982",
                            "@type": "electronic"
                        },
                        {
                            "$": "03331024",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2023"},
                    "publisher": {"publishername": "SAGE Publications Ltd"},
                    "@srcid": "14841"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                },
                                {
                                    "classification-code": "8",
                                    "classification-description": "Neurology and Neurosurgery"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2728"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": "83652-28-2",
                                    "chemical-name": "calcitonin gene related peptide"
                                },
                                {
                                    "cas-registry-number": "1578199-75-3",
                                    "chemical-name": "galcanezumab"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Antibodies, Monoclonal"},
                                {"chemical-name": "Calcitonin Gene-Related Peptide"}
                            ]
                        }
                    ]}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2023 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "26",
                    "@timestamp": "BST 05:04:54",
                    "@year": "2023",
                    "@month": "05"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2023239534",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "640681493",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "948250921",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20230468210",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "36924253",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20231388023",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20231852062",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20239015058619",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85150314244",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85150314244",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "640681493",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "76295299",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1177/03331024231161261"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "34",
                "reference": [
                    {
                        "ref-fulltext": "Blumenfeld AM Varon SF Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011; 31: 301\u2013315.",
                        "@reference-instance-id": "OB2BibRecID-948250921-ed081aa1d5a1ea1e756e64c3ba41cc82-1",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr1-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79953215700",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {
                                    "@first": "301",
                                    "@last": "315"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Blumenfeld",
                                        "ce:indexed-name": "Blumenfeld A.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Varon",
                                        "ce:indexed-name": "Varon S.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Wilcox",
                                        "ce:indexed-name": "Wilcox T.K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cephalalgia"
                        },
                        "ce:source-text": "Blumenfeld AM Varon SF Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011; 31: 301\u2013315."
                    },
                    {
                        "ref-fulltext": "Buse DC Greisman JD Baigi K, et al. Migraine progression: a systematic review. Headache 2019; 59: 306\u2013338.",
                        "@reference-instance-id": "OB2BibRecID-948250921-559a49784dbd02148ec8ba6334973161-2",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Migraine progression: a systematic review"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr2-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85059119708",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "59"},
                                "pagerange": {
                                    "@first": "306",
                                    "@last": "338"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Buse",
                                        "ce:indexed-name": "Buse D.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Greisman",
                                        "ce:indexed-name": "Greisman J.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Baigi",
                                        "ce:indexed-name": "Baigi K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Buse DC Greisman JD Baigi K, et al. Migraine progression: a systematic review. Headache 2019; 59: 306\u2013338."
                    },
                    {
                        "ref-fulltext": "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1\u2013211.",
                        "@reference-instance-id": "OB2BibRecID-948250921-0f24b4bc4711d4d0a6e38ea9a09bfa92-3",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "The International Classification of Headache Disorders, 3rd edition"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr3-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85042638149",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "211"
                                }
                            },
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Headache Classification Committee of the International Headache Society (IHS)",
                                "ce:indexed-name": "Headache Classification Committee of the International Headache Society (IHS)"
                            }},
                            "ref-sourcetitle": "Cephalalgia"
                        },
                        "ce:source-text": "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1\u2013211."
                    },
                    {
                        "ref-fulltext": "Jedynak J Eross E Gendolla A, et al. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials. J Headache Pain 2021; 22: 48.",
                        "@reference-instance-id": "OB2BibRecID-948250921-5ea74723299ca76b6ec2c39ead396d33-4",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr4-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85106958978",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {"@first": "48"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Jedynak",
                                        "ce:indexed-name": "Jedynak J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Eross",
                                        "ce:indexed-name": "Eross E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Gendolla",
                                        "ce:indexed-name": "Gendolla A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Headache Pain"
                        },
                        "ce:source-text": "Jedynak J Eross E Gendolla A, et al. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials. J Headache Pain 2021; 22: 48."
                    },
                    {
                        "ref-fulltext": "Ailani J Burch RC Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021; 61: 1021\u20131039.",
                        "@reference-instance-id": "OB2BibRecID-948250921-4f32926401599847d6fbd3923dd40bb5-5",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr5-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85108990860",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "61"},
                                "pagerange": {
                                    "@first": "1021",
                                    "@last": "1039"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Ailani",
                                    "ce:indexed-name": "Ailani J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Burch",
                                    "ce:indexed-name": "Burch R.C."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Robbins",
                                    "ce:indexed-name": "Robbins M.S."
                                }
                            ]},
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Ailani J Burch RC Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021; 61: 1021\u20131039."
                    },
                    {
                        "ref-fulltext": "Tso AR Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Opt Neurol 2017; 19: 27.",
                        "@reference-instance-id": "OB2BibRecID-948250921-b44789c4db5f245cd0cdc03e695adba4-6",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Anti-CGRP monoclonal antibodies: the next era of migraine prevention?"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr6-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85021385594",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "19"},
                                "pagerange": {"@first": "27"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.R.",
                                    "@_fa": "true",
                                    "ce:surname": "Tso",
                                    "ce:indexed-name": "Tso A.R."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "P.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Goadsby",
                                    "ce:indexed-name": "Goadsby P.J."
                                }
                            ]},
                            "ref-sourcetitle": "Curr Treat Opt Neurol"
                        },
                        "ce:source-text": "Tso AR Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Opt Neurol 2017; 19: 27."
                    },
                    {
                        "ref-fulltext": "Sacco S Bendtsen L Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 2019; 20: 6.",
                        "@reference-instance-id": "OB2BibRecID-948250921-d584f598e6b05681d96a2b6a855c74bf-7",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr7-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85060137029",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {"@first": "6"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Sacco",
                                        "ce:indexed-name": "Sacco S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bendtsen",
                                        "ce:indexed-name": "Bendtsen L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ashina",
                                        "ce:indexed-name": "Ashina M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Headache Pain"
                        },
                        "ce:source-text": "Sacco S Bendtsen L Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 2019; 20: 6."
                    },
                    {
                        "ref-fulltext": "Kielbasa W Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 2019; 39: 1284\u20131297.",
                        "@reference-instance-id": "OB2BibRecID-948250921-f66db31e16f55b2938e0d6feeb5daa38-8",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr8-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85063645596",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "39"},
                                "pagerange": {
                                    "@first": "1284",
                                    "@last": "1297"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "W.",
                                    "@_fa": "true",
                                    "ce:surname": "Kielbasa",
                                    "ce:indexed-name": "Kielbasa W."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Helton",
                                    "ce:indexed-name": "Helton D.L."
                                }
                            ]},
                            "ref-sourcetitle": "Cephalalgia"
                        },
                        "ce:source-text": "Kielbasa W Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 2019; 39: 1284\u20131297."
                    },
                    {
                        "ref-fulltext": "Scuteri D Adornetto A RombolÃ  L, et al. New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol 2019; 10: 363.",
                        "@reference-instance-id": "OB2BibRecID-948250921-9b39e788a2a9488727c2a32955cd6866-9",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr9-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85068375351",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "10"},
                                "pagerange": {"@first": "363"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Scuteri",
                                        "ce:indexed-name": "Scuteri D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Adornetto",
                                        "ce:indexed-name": "Adornetto A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "RombolÃ ",
                                        "ce:indexed-name": "Rombola L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Pharmacol"
                        },
                        "ce:source-text": "Scuteri D Adornetto A RombolÃ  L, et al. New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol 2019; 10: 363."
                    },
                    {
                        "ref-fulltext": "Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Movement Disorders 2005; 20: S11\u201316.",
                        "@reference-instance-id": "OB2BibRecID-948250921-17803f3b3c3579b3bc4b1668ab339acf-10",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2005"},
                            "ref-title": {"ref-titletext": "Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr10-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "20444489689",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {
                                    "@first": "S11",
                                    "@last": "S16"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "J.",
                                "@_fa": "true",
                                "ce:surname": "Jankovic",
                                "ce:indexed-name": "Jankovic J."
                            }]},
                            "ref-sourcetitle": "Movement Disorders"
                        },
                        "ce:source-text": "Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Movement Disorders 2005; 20: S11\u201316."
                    },
                    {
                        "ref-fulltext": "Matharu M Pascual J Nilsson Remahl I, et al. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia 2017; 37: 1384\u20131397.",
                        "@reference-instance-id": "OB2BibRecID-948250921-a368a45df487fdc41e40436d019f9e36-11",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr11-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85038368110",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "37"},
                                "pagerange": {
                                    "@first": "1384",
                                    "@last": "1397"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Matharu",
                                        "ce:indexed-name": "Matharu M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Pascual",
                                        "ce:indexed-name": "Pascual J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Nilsson Remahl",
                                        "ce:indexed-name": "Nilsson Remahl I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cephalalgia"
                        },
                        "ce:source-text": "Matharu M Pascual J Nilsson Remahl I, et al. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia 2017; 37: 1384\u20131397."
                    },
                    {
                        "ref-fulltext": "Khan FA Mohammed AE Poongkunran M, et al. Wearing off effect of onabotulinumtoxina near the end of treatment cycle for chronic migraine: a 4-year clinical experience. Headache 2020; 60: 430\u2013440.",
                        "@reference-instance-id": "OB2BibRecID-948250921-b687d55e8a5c2b69ec87f25277419cd1-12",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Wearing off effect of onabotulinumtoxina near the end of treatment cycle for chronic migraine: a 4-year clinical experience"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr12-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075434605",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "60"},
                                "pagerange": {
                                    "@first": "430",
                                    "@last": "440"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Khan",
                                        "ce:indexed-name": "Khan F.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Mohammed",
                                        "ce:indexed-name": "Mohammed A.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Poongkunran",
                                        "ce:indexed-name": "Poongkunran M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Khan FA Mohammed AE Poongkunran M, et al. Wearing off effect of onabotulinumtoxina near the end of treatment cycle for chronic migraine: a 4-year clinical experience. Headache 2020; 60: 430\u2013440."
                    },
                    {
                        "ref-fulltext": "Masters-Israilov A Robbins MS. OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine. Headache 2019; 59: 1753\u20131761.",
                        "@reference-instance-id": "OB2BibRecID-948250921-e24513dcecd1edac43172adc3da908dd-13",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr13-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85073831725",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "59"},
                                "pagerange": {
                                    "@first": "1753",
                                    "@last": "1761"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Masters-Israilov",
                                    "ce:indexed-name": "Masters-Israilov A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Robbins",
                                    "ce:indexed-name": "Robbins M.S."
                                }
                            ]},
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Masters-Israilov A Robbins MS. OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine. Headache 2019; 59: 1753\u20131761."
                    },
                    {
                        "ref-fulltext": "Quintas S GarcÃ­a-AzorÃ­n D Heredia P, et al. Wearing off response to onabotulinumtoxina in chronic migraine: analysis in a series of 193 patients. Pain Med (Malden, Mass) 2019; 20: 1815\u20131821.",
                        "@reference-instance-id": "OB2BibRecID-948250921-01ec0b723e547181386e9df407345e2f-14",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Wearing off response to onabotulinumtoxina in chronic migraine: analysis in a series of 193 patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr14-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85073829668",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {
                                    "@first": "1815",
                                    "@last": "1821"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Quintas",
                                        "ce:indexed-name": "Quintas S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "GarcÃ­a-AzorÃ­n",
                                        "ce:indexed-name": "Garcia-Azorin D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Heredia",
                                        "ce:indexed-name": "Heredia P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Pain Med (Malden, Mass)"
                        },
                        "ce:source-text": "Quintas S GarcÃ­a-AzorÃ­n D Heredia P, et al. Wearing off response to onabotulinumtoxina in chronic migraine: analysis in a series of 193 patients. Pain Med (Malden, Mass) 2019; 20: 1815\u20131821."
                    },
                    {
                        "ref-fulltext": "Garcia-Ayala ME Veronesi MA Verhaak A, et al. Calcitonin gene-related peptide (CGRP) monoclonal antibody (MAB) wear-off phenomenon in the treatment of migraine. Headache 2021; 61: 56.",
                        "@reference-instance-id": "OB2BibRecID-948250921-47c06a9de63a9a4d5e77171d536ec855-15",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Calcitonin gene-related peptide (CGRP) monoclonal antibody (MAB) wear-off phenomenon in the treatment of migraine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr15-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85159614189",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "61"},
                                "pagerange": {"@first": "56"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Garcia-Ayala",
                                        "ce:indexed-name": "Garcia-Ayala M.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Veronesi",
                                        "ce:indexed-name": "Veronesi M.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Verhaak",
                                        "ce:indexed-name": "Verhaak A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Garcia-Ayala ME Veronesi MA Verhaak A, et al. Calcitonin gene-related peptide (CGRP) monoclonal antibody (MAB) wear-off phenomenon in the treatment of migraine. Headache 2021; 61: 56."
                    },
                    {
                        "ref-fulltext": "Robblee J Devick KL Mendez N, et al. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 2020; 60: 2014\u20132025.",
                        "@reference-instance-id": "OB2BibRecID-948250921-2570f0b7516aa4ecb4ad69a894260c46-16",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Real-world patient experience with erenumab for the preventive treatment of migraine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr16-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85090991112",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "60"},
                                "pagerange": {
                                    "@first": "2014",
                                    "@last": "2025"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Robblee",
                                        "ce:indexed-name": "Robblee J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Devick",
                                        "ce:indexed-name": "Devick K.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Mendez",
                                        "ce:indexed-name": "Mendez N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Robblee J Devick KL Mendez N, et al. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 2020; 60: 2014\u20132025."
                    },
                    {
                        "ref-fulltext": "Feldman D George N Reed D. The aimovig \u201cwear-off\u201d: A retrospective review. Cephalalgia 2019; 39: 256.",
                        "@reference-instance-id": "OB2BibRecID-948250921-9c828d828821d13c3ab8b0dee17a2a79-17",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "The aimovig \u201cwear-off\u201d: A retrospective review"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr17-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85096328260",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "39"},
                                "pagerange": {"@first": "256"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Feldman",
                                    "ce:indexed-name": "Feldman D."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "George",
                                    "ce:indexed-name": "George N."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Reed",
                                    "ce:indexed-name": "Reed D."
                                }
                            ]},
                            "ref-sourcetitle": "Cephalalgia"
                        },
                        "ce:source-text": "Feldman D George N Reed D. The aimovig \u201cwear-off\u201d: A retrospective review. Cephalalgia 2019; 39: 256."
                    },
                    {
                        "ref-fulltext": "Blumenfeld AM Stevanovic DM Ortega M, et al. No \u201cwearing-off effect\u201d seen in quarterly or monthly dosing of fremanezumab: subanalysis of a randomized long-term study. Headache 2020; 60: 2431\u20132443.",
                        "@reference-instance-id": "OB2BibRecID-948250921-68df0d4bebbb72da87d432adf87f6c7a-18",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "wearing-off effect\u201d seen in quarterly or monthly dosing of fremanezumab: subanalysis of a randomized long-term study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr18-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85094631714",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "60"},
                                "pagerange": {
                                    "@first": "2431",
                                    "@last": "2443"
                                }
                            },
                            "ref-text": "No",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Blumenfeld",
                                        "ce:indexed-name": "Blumenfeld A.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Stevanovic",
                                        "ce:indexed-name": "Stevanovic D.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ortega",
                                        "ce:indexed-name": "Ortega M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Blumenfeld AM Stevanovic DM Ortega M, et al. No \u201cwearing-off effect\u201d seen in quarterly or monthly dosing of fremanezumab: subanalysis of a randomized long-term study. Headache 2020; 60: 2431\u20132443."
                    },
                    {
                        "ref-fulltext": "Pozo-Rosich P Samaan KH Schwedt TJ, et al. Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis. Adv Therapy 2021; 38: 3154\u20133165.",
                        "@reference-instance-id": "OB2BibRecID-948250921-ce085f6ee4321b459d73720f0cf5570b-19",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr19-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85105539670",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "3154",
                                    "@last": "3165"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Pozo-Rosich",
                                        "ce:indexed-name": "Pozo-Rosich P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Samaan",
                                        "ce:indexed-name": "Samaan K.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schwedt",
                                        "ce:indexed-name": "Schwedt T.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Adv Therapy"
                        },
                        "ce:source-text": "Pozo-Rosich P Samaan KH Schwedt TJ, et al. Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis. Adv Therapy 2021; 38: 3154\u20133165."
                    },
                    {
                        "ref-fulltext": "Schwedt TJ Kuruppu DK Dong Y, et al. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain 2021; 22: 15.",
                        "@reference-instance-id": "OB2BibRecID-948250921-f91edaf9ce29ee6faef1bcc93c3ccd54-20",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr20-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85103381199",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {"@first": "15"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schwedt",
                                        "ce:indexed-name": "Schwedt T.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Kuruppu",
                                        "ce:indexed-name": "Kuruppu D.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Dong",
                                        "ce:indexed-name": "Dong Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Headache Pain"
                        },
                        "ce:source-text": "Schwedt TJ Kuruppu DK Dong Y, et al. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain 2021; 22: 15."
                    },
                    {
                        "ref-fulltext": "Blaiss C Stevanovic D Cohen J, et al. Quarterly administration of fremanezumab does not show \u201cwearing off\u201d effect during third month after injection (P2.10-013). Neurology 2019; 92: P2.10-013.",
                        "@reference-instance-id": "OB2BibRecID-948250921-d4109ac7e1eec2be40a9c797f712d3ea-21",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Quarterly administration of fremanezumab does not show \u201cwearing off\u201d effect during third month after injection (P2.10-013)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr21-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075156477",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "92"}},
                            "ref-text": "P2.10-013",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Blaiss",
                                        "ce:indexed-name": "Blaiss C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Stevanovic",
                                        "ce:indexed-name": "Stevanovic D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Neurology"
                        },
                        "ce:source-text": "Blaiss C Stevanovic D Cohen J, et al. Quarterly administration of fremanezumab does not show \u201cwearing off\u201d effect during third month after injection (P2.10-013). Neurology 2019; 92: P2.10-013."
                    },
                    {
                        "ref-fulltext": "Ailani J Kuruppu DK Rettiganti M, et al. Does \u201cwearing off\u201d of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials. Headache 2022; 62: 198\u2013207.",
                        "@reference-instance-id": "OB2BibRecID-948250921-a326c544627a5fbd53f2484ebedc5c11-22",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Does \u201cwearing off\u201d of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr22-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85123641873",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "62"},
                                "pagerange": {
                                    "@first": "198",
                                    "@last": "207"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ailani",
                                        "ce:indexed-name": "Ailani J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Kuruppu",
                                        "ce:indexed-name": "Kuruppu D.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Rettiganti",
                                        "ce:indexed-name": "Rettiganti M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Ailani J Kuruppu DK Rettiganti M, et al. Does \u201cwearing off\u201d of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials. Headache 2022; 62: 198\u2013207."
                    },
                    {
                        "ref-fulltext": "Moher D Liberati A Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.",
                        "@reference-instance-id": "OB2BibRecID-948250921-6958bffac047508127ecfc9d70bcfd43-23",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr23-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "68049122102",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "6"},
                                "pagerange": {"@first": "e1000097"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Moher",
                                        "ce:indexed-name": "Moher D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Liberati",
                                        "ce:indexed-name": "Liberati A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Tetzlaff",
                                        "ce:indexed-name": "Tetzlaff J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "PLoS Med"
                        },
                        "ce:source-text": "Moher D Liberati A Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097."
                    },
                    {
                        "ref-fulltext": "DerSimonian R Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986; 7: 177\u2013188.",
                        "@reference-instance-id": "OB2BibRecID-948250921-81bf481281ac6fb6d70f04cc9af9b7a0-24",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1986"},
                            "ref-title": {"ref-titletext": "Meta-analysis in clinical trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr24-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0022992740",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "7"},
                                "pagerange": {
                                    "@first": "177",
                                    "@last": "188"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "DerSimonian",
                                    "ce:indexed-name": "DerSimonian R."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Laird",
                                    "ce:indexed-name": "Laird N."
                                }
                            ]},
                            "ref-sourcetitle": "Contr Clin Trials"
                        },
                        "ce:source-text": "DerSimonian R Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986; 7: 177\u2013188."
                    },
                    {
                        "ref-fulltext": "Higgins JP Thompson SG Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557\u2013560.",
                        "@reference-instance-id": "OB2BibRecID-948250921-82ceaa8856bd45c4e60cb1392c8f7434-25",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2003"},
                            "ref-title": {"ref-titletext": "Measuring inconsistency in meta-analyses"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr25-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0041876133",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "327"},
                                "pagerange": {
                                    "@first": "557",
                                    "@last": "560"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Higgins",
                                        "ce:indexed-name": "Higgins J.P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Thompson",
                                        "ce:indexed-name": "Thompson S.G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Deeks",
                                        "ce:indexed-name": "Deeks J.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BMJ"
                        },
                        "ce:source-text": "Higgins JP Thompson SG Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557\u2013560."
                    },
                    {
                        "ref-fulltext": "Easterbrook PJ Berlin JA Gopalan R, et al. Publication bias in clinical research. Lancet 1991; 337: 867\u2013872.",
                        "@reference-instance-id": "OB2BibRecID-948250921-8d112f219ecdd462c053d03e75eadd1f-26",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1991"},
                            "ref-title": {"ref-titletext": "Publication bias in clinical research"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr26-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0025794172",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "337"},
                                "pagerange": {
                                    "@first": "867",
                                    "@last": "872"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Easterbrook",
                                        "ce:indexed-name": "Easterbrook P.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Berlin",
                                        "ce:indexed-name": "Berlin J.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Gopalan",
                                        "ce:indexed-name": "Gopalan R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Easterbrook PJ Berlin JA Gopalan R, et al. Publication bias in clinical research. Lancet 1991; 337: 867\u2013872."
                    },
                    {
                        "ref-fulltext": "Anzures-Cabrera J Higgins JP. Graphical displays for meta-analysis: An overview with suggestions for practice. Res Synth Methods 2010; 1: 66\u201380.",
                        "@reference-instance-id": "OB2BibRecID-948250921-c74e90afce97a03691fe31ed5c80fb77-27",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Graphical displays for meta-analysis: An overview with suggestions for practice"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr27-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79957558500",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "1"},
                                "pagerange": {
                                    "@first": "66",
                                    "@last": "80"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Anzures-Cabrera",
                                    "ce:indexed-name": "Anzures-Cabrera J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.P.",
                                    "@_fa": "true",
                                    "ce:surname": "Higgins",
                                    "ce:indexed-name": "Higgins J.P."
                                }
                            ]},
                            "ref-sourcetitle": "Res Synth Methods"
                        },
                        "ce:source-text": "Anzures-Cabrera J Higgins JP. Graphical displays for meta-analysis: An overview with suggestions for practice. Res Synth Methods 2010; 1: 66\u201380."
                    },
                    {
                        "ref-fulltext": "Starling AJ Cohen JM Ramirez Campos V, et al. No evidence of wearing off effect for fremanezumab treatment in chronic and episodic migraine patients with inadequate response to 2\u20134 prior classes of migraine preventive medications. Headache 2021; 61: 134.",
                        "@reference-instance-id": "OB2BibRecID-948250921-d43d90c8156388041d8fc786d53dd1af-28",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "No evidence of wearing off effect for fremanezumab treatment in chronic and episodic migraine patients with inadequate response to 2\u20134 prior classes of migraine preventive medications"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr28-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85159573477",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "61"},
                                "pagerange": {"@first": "134"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Starling",
                                        "ce:indexed-name": "Starling A.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen J.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Ramirez Campos",
                                        "ce:indexed-name": "Ramirez Campos V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Headache"
                        },
                        "ce:source-text": "Starling AJ Cohen JM Ramirez Campos V, et al. No evidence of wearing off effect for fremanezumab treatment in chronic and episodic migraine patients with inadequate response to 2\u20134 prior classes of migraine preventive medications. Headache 2021; 61: 134."
                    },
                    {
                        "ref-fulltext": "Spierings ELH KÃ¤rppÃ¤ M Ning X, et al. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial. J Headache Pain 2021; 22: 26.",
                        "@reference-instance-id": "OB2BibRecID-948250921-df9a48e7b326b614cb8aa9339a54f511-29",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr29-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85104389148",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {"@first": "26"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.L.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Spierings",
                                        "ce:indexed-name": "Spierings E.L.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "KÃ¤rppÃ¤",
                                        "ce:indexed-name": "Karppa M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Ning",
                                        "ce:indexed-name": "Ning X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Headache Pain"
                        },
                        "ce:source-text": "Spierings ELH KÃ¤rppÃ¤ M Ning X, et al. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial. J Headache Pain 2021; 22: 26."
                    },
                    {
                        "ref-fulltext": "Stauffer VL Dodick DW Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 2018; 75: 1080\u20131088.",
                        "@reference-instance-id": "OB2BibRecID-948250921-299c7c2819a86d847a861d0c7b203a98-30",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr30-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85051141853",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "75"},
                                "pagerange": {
                                    "@first": "1080",
                                    "@last": "1088"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Stauffer",
                                        "ce:indexed-name": "Stauffer V.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Dodick",
                                        "ce:indexed-name": "Dodick D.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang Q."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Neurol"
                        },
                        "ce:source-text": "Stauffer VL Dodick DW Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 2018; 75: 1080\u20131088."
                    },
                    {
                        "ref-fulltext": "Skljarevski V Matharu M Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38: 1442\u20131454.",
                        "@reference-instance-id": "OB2BibRecID-948250921-82c26199b3442f7d75b2005d98c4e83f-31",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr31-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85047920701",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "1442",
                                    "@last": "1454"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Skljarevski",
                                        "ce:indexed-name": "Skljarevski V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Matharu",
                                        "ce:indexed-name": "Matharu M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Millen",
                                        "ce:indexed-name": "Millen B.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cephalalgia"
                        },
                        "ce:source-text": "Skljarevski V Matharu M Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38: 1442\u20131454."
                    },
                    {
                        "ref-fulltext": "Mulleners WM Kim B-K LÃ¡inez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020; 19: 814\u2013825.",
                        "@reference-instance-id": "OB2BibRecID-948250921-8b1d042ec8c687f190eabddd213b84a7-32",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr32-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85090896366",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "19"},
                                "pagerange": {
                                    "@first": "814",
                                    "@last": "825"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "W.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Mulleners",
                                        "ce:indexed-name": "Mulleners W.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.-K.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim B.-K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "LÃ¡inez",
                                        "ce:indexed-name": "Lainez M.J.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Neurol"
                        },
                        "ce:source-text": "Mulleners WM Kim B-K LÃ¡inez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020; 19: 814\u2013825."
                    },
                    {
                        "ref-fulltext": "Detke HC Goadsby PJ Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91: e2211\u2013e2221.",
                        "@reference-instance-id": "OB2BibRecID-948250921-de37f22856d4f56e94e457430dccca58-33",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr33-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058611353",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "91"},
                                "pagerange": {
                                    "@first": "e2211",
                                    "@last": "e2221"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Detke",
                                        "ce:indexed-name": "Detke H.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Goadsby",
                                        "ce:indexed-name": "Goadsby P.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Neurology"
                        },
                        "ce:source-text": "Detke HC Goadsby PJ Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91: e2211\u2013e2221."
                    },
                    {
                        "ref-fulltext": "Jackson D Turner R. Power analysis for random-effects meta-analysis. Res Syn Meth 2017; 8: 290\u2013302.",
                        "@reference-instance-id": "OB2BibRecID-948250921-cbf72422f3b3659c06587f66f5c784f6-34",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Power analysis for random-effects meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr34-03331024231161261",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85017336537",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {
                                    "@first": "290",
                                    "@last": "302"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Jackson",
                                    "ce:indexed-name": "Jackson D."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Turner",
                                    "ce:indexed-name": "Turner R."
                                }
                            ]},
                            "ref-sourcetitle": "Res Syn Meth"
                        },
                        "ce:source-text": "Jackson D Turner R. Power analysis for random-effects meta-analysis. Res Syn Meth 2017; 8: 290\u2013302."
                    }
                ]
            }}
        }
    },
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60002620",
        "affilname": "Faculty of Medicine, Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
        "affiliation-country": "Thailand"
    },
    "coredata": {
        "srctype": "j",
        "prism:issueIdentifier": "4",
        "eid": "2-s2.0-85150314244",
        "dc:description": "Background: A new migraine prevention, CGRP monoclonal antibodies (mAbs), is injectable on a monthly or quarterly basis. In clinical practice, some patients reported that drug effectiveness does not last until the upcoming scheduled injection, a so-called \u201cwearing-off\u201d effect. We aimed to evaluate the wearing-off effect of the CGRP mAbs for migraine prevention in patients with different monthly migraine days. Methods: We conducted a literature search for studies that reported migraine frequency after CGRP monoclonal antibody administration from MEDLINE, SCOPUS, Web of Science, and Cochrane Database from inception through February 2022. A meta-analysis, random-effects model was applied to assess the difference in migraine frequency between early and later weeks after medication to assess the presence of a wearing-off effect. Risk ratio was calculated to report the pooled treatment effect. Results: Four studies were entered for the analysis, comprising 2409 patients in randomized controlled trials. There was no association between CGRP mAbs and wearing-off effect in patients with galcanezumab with a pooled risk ratio of 1.29 (95% CI 0.73 to 2.28) compared to placebo group. However, there was an association between galcanezumab and wearing-off effect in patients with chronic migraine with a pooled risk ratio of 1.91 (95% CI 1.11 to 3.28) compared to placebo group. Conclusion: In this meta-analysis, there was a wearing-off efficacy of galcanezumab but only in a small percentage of patients with chronic migraine in randomized controlled trials.",
        "pubmed-id": "36924253",
        "prism:coverDate": "2023-04-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85150314244",
        "subtypeDescription": "Article",
        "dc:creator": {"author": [{
            "ce:given-name": "Thanin",
            "preferred-name": {
                "ce:given-name": "Thanin",
                "ce:initials": "T.",
                "ce:surname": "Asawavichienjinda",
                "ce:indexed-name": "Asawavichienjinda T."
            },
            "@seq": "1",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Asawavichienjinda",
            "@auid": "6603247860",
            "author-url": "https://api.elsevier.com/content/author/author_id/6603247860",
            "ce:indexed-name": "Asawavichienjinda T."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85150314244"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150314244&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85150314244&origin=inward"
            }
        ],
        "prism:publicationName": "Cephalalgia",
        "source-id": "14841",
        "citedby-count": "0",
        "prism:volume": "43",
        "subtype": "ar",
        "dc:title": "\u201cWearing-off\u201d efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials",
        "openaccess": "1",
        "openaccessFlag": "true",
        "prism:doi": "10.1177/03331024231161261",
        "prism:issn": "14682982 03331024",
        "publishercopyright": "Â© The Author(s) 2023.",
        "dc:identifier": "SCOPUS_ID:85150314244",
        "dc:publisher": "SAGE Publications Ltd"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Antibodies, Monoclonal",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Calcitonin Gene-Related Peptide",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Migraine Disorders",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Randomized Controlled Trials as Topic",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Treatment Outcome",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "CGRP monoclonal antibodies"
        },
        {
            "@_fa": "true",
            "$": "effect"
        },
        {
            "@_fa": "true",
            "$": "migraine prevention"
        },
        {
            "@_fa": "true",
            "$": "prophylaxis"
        },
        {
            "@_fa": "true",
            "$": "Wearing-off efficacy"
        }
    ]},
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Neurology (clinical)",
        "@code": "2728",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Thanin",
            "preferred-name": {
                "ce:given-name": "Thanin",
                "ce:initials": "T.",
                "ce:surname": "Asawavichienjinda",
                "ce:indexed-name": "Asawavichienjinda T."
            },
            "@seq": "1",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Asawavichienjinda",
            "@auid": "6603247860",
            "author-url": "https://api.elsevier.com/content/author/author_id/6603247860",
            "ce:indexed-name": "Asawavichienjinda T."
        },
        {
            "ce:given-name": "Seelwan",
            "preferred-name": {
                "ce:given-name": "Seelwan",
                "ce:initials": "S.",
                "ce:surname": "Sathitratanacheewin",
                "ce:indexed-name": "Sathitratanacheewin S."
            },
            "@seq": "2",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Sathitratanacheewin",
            "@auid": "57199324342",
            "author-url": "https://api.elsevier.com/content/author/author_id/57199324342",
            "ce:indexed-name": "Sathitratanacheewin S."
        },
        {
            "ce:given-name": "Ronpichai",
            "preferred-name": {
                "ce:given-name": "Ronpichai",
                "ce:initials": "R.",
                "ce:surname": "Chokesuwattanaskul",
                "ce:indexed-name": "Chokesuwattanaskul R."
            },
            "@seq": "3",
            "ce:initials": "R.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Chokesuwattanaskul",
            "@auid": "57202543782",
            "author-url": "https://api.elsevier.com/content/author/author_id/57202543782",
            "ce:indexed-name": "Chokesuwattanaskul R."
        }
    ]}
}}